Innovation Pharmaceuticals Inc
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company has a license agree… Read more
Innovation Pharmaceuticals Inc (IPIX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2023: -0.583x
Based on the latest financial reports, Innovation Pharmaceuticals Inc (IPIX) has a cash flow conversion efficiency ratio of -0.583x as of September 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-677.00K) by net assets ($1.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Innovation Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2007–2023)
This chart illustrates how Innovation Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Innovation Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Innovation Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DENTSPLY INTL
MU:DY2
|
0.057x |
|
HOSTMORE LTD GB -20
F:9UX
|
N/A |
|
NISSHIN SEIFUN GRP
DU:NFR
|
N/A |
|
Raontec Inc.
KO:232680
|
N/A |
|
Jura Energy Corporation
PINK:JECFF
|
-0.256x |
|
Unibet Group plc
STU:UNBA
|
0.102x |
|
PRIO3F
SA:PRIO3F
|
N/A |
|
PRIMARIS REIT A
F:H0D
|
N/A |
Annual Cash Flow Conversion Efficiency for Innovation Pharmaceuticals Inc (2007–2023)
The table below shows the annual cash flow conversion efficiency of Innovation Pharmaceuticals Inc from 2007 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-06-30 | $2.04 Million | $-2.11 Million | -1.033x | +22.21% |
| 2022-06-30 | $4.73 Million | $-6.28 Million | -1.328x | -5.00% |
| 2021-06-30 | $7.51 Million | $-9.49 Million | -1.264x | +55.52% |
| 2020-06-30 | $1.46 Million | $-4.16 Million | -2.843x | -285.37% |
| 2019-06-30 | $-4.13 Million | $-6.33 Million | 1.534x | -75.16% |
| 2018-06-30 | $-2.15 Million | $-13.28 Million | 6.173x | -22.83% |
| 2017-06-30 | $-1.46 Million | $-11.71 Million | 7.999x | +339.81% |
| 2016-06-30 | $2.96 Million | $-9.89 Million | -3.336x | -79.25% |
| 2015-06-30 | $7.02 Million | $-13.07 Million | -1.861x | +70.12% |
| 2014-06-30 | $1.21 Million | $-7.51 Million | -6.227x | -1787.85% |
| 2013-06-30 | $-5.17 Million | $-1.91 Million | 0.369x | +305.49% |
| 2012-06-30 | $-7.63 Million | $-693.86K | 0.091x | -9.87% |
| 2011-06-30 | $-7.29 Million | $-735.70K | 0.101x | -56.34% |
| 2010-06-30 | $-4.80 Million | $-1.11 Million | 0.231x | +96.04% |
| 2009-06-30 | $-1.79 Million | $-211.48K | 0.118x | -46.96% |
| 2008-06-30 | $-361.99K | $-80.50K | 0.222x | +170.25% |
| 2007-06-30 | $18.67K | $-5.91K | -0.317x | -- |